| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/21678421.2017.1418001 |
| P698 | PubMed publication ID | 29260911 |
| P50 | author | Emily Leary | Q86831079 |
| Iyas Daghlas | Q90985042 | ||
| P2093 | author name string | Teresa E Lever | |
| P2860 | cites work | Clinical significance in the change of decline in ALSFRS-R | Q22305679 |
| The PRO-ACT database: design, initial analyses, and predictive features | Q28651661 | ||
| Fitting Linear Mixed-Effects Models Using lme4 | Q30477923 | ||
| The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies | Q33617148 | ||
| ALSFRS-R. | Q34362989 | ||
| Robustness of the two independent samples t-test when applied to ordinal scaled data | Q36466012 | ||
| A joint model for survival and longitudinal data measured with error | Q36860282 | ||
| The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset | Q37107393 | ||
| Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis | Q39948325 | ||
| Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy | Q41553914 | ||
| Twelve Frequently Asked Questions About Growth Curve Modeling | Q42789476 | ||
| Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial | Q43239620 | ||
| Likert scales, levels of measurement and the "laws" of statistics | Q47265530 | ||
| What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis | Q48033371 | ||
| Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. | Q51066498 | ||
| Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. | Q51439936 | ||
| Progression in ALS is not linear but is curvilinear. | Q51691332 | ||
| The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 | ||
| Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. | Q55041563 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| covariate | Q5178903 | ||
| P304 | page(s) | 206-211 | |
| P577 | publication date | 2017-12-20 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | Q23928840 |
| P1476 | title | A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials | |
| P478 | volume | 19 |
| Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS | cites work | P2860 |
Search more.